Results 51 to 60 of about 65,257 (310)
Guillain–Barré syndrome in low-income and middle-income countries: challenges and prospects
Nature Reviews Neurology, 2021 The epidemiology, clinical characteristics, management and outcome of Guillain–Barré syndrome (GBS) differ between low-income and middle-income countries (LMIC) and high-income countries (HIC).
Nowshin Papri +5 more
semanticscholar +1 more source
Journal of Medical Case Reports, 2021 Introduction The novel coronavirus, since its first identification in China, in December 2019, has shown remarkable heterogeneity in its clinical behavior. It has affected humans on every continent. Clinically, it has affected every organ system.
Ahmed Maseh Haidary +13 more
doaj +1 more source
Kazan medical journal, 2015 Guillain-Barre syndrome is an acute inflammatory demyelinating polyradiculoneuropathy of autoimmune etiology, which is characterized by peripheral paralysis and protein-cell dissociation in the cerebrospinal fluid in most cases. The Guillain-Barre syndrome prevalence is 0.6-2.4 cases per 100 thousand population.
D E Kutepov, N I Litvinov
openaire +3 more sources
Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
JAMA Internal Medicine, 2021 Importance Guillain-Barré syndrome can be reported after vaccination. This study assesses the risk of Guillain-Barré syndrome after administration of recombinant zoster vaccine (RZV or Shingrix), which is administered in 2 doses 2 to 6 months apart ...
Ravi Goud +14 more
semanticscholar +1 more source
Neuropathophysiological potential of Guillain-Barré syndrome anti-ganglioside-complex antibodies at mouse motor nerve terminals [PDF]
, 2011 Objectives: Anti-ganglioside antibodies are present in approximately half of Guillain–Barré syndrome (GBS) patients. Recently, it has been shown that a considerable proportion of these patients has serum antibodies against antigenic epitopes formed by a
Goodfellow +22 more
core +1 more source
Nepalese Medical Journal, 2019 Introduction: Intravenous Immunoglobulin is an approved therapy for Guillain Barre Syndrome. Our objective is to understand the management and outcome in Guillain Barre Syndrome patients treated with Immunoglobulin. Materials and Methods: All consecutive
Rajeev Ojha, Ragesh Karn
doaj +1 more source
Guillain-Barre syndrome and mood disorders [PDF]
Annals of General Psychiatry, 2010 Background Guillain-Barre syndrome (GBS) is an acute, autoimmune polyradiculoneuropathy affecting the peripheral nervous system, usually triggered by an acute infectious process. It is included in the wider group of peripheral neuropathies. There are several types of GBS, but unless otherwise stated, GBS refers to the most common form, acute ...
Giorgos Vagionis +2 more
openaire +3 more sources
Case of Guillain-Barré syndrome following COVID-19 vaccine
BMJ Case Reports, 2021 Guillain-Barré syndrome (GBS) is a rare immune-mediated disorder of the peripheral nerves. Although its cause is not fully understood, the syndrome often follows infection with a virus or bacteria, although in rare occasions, vaccination may precede GBS.
T. Hasan +3 more
semanticscholar +1 more source
Autoimmune neurological conditions associated with Zika virus infection [PDF]
, 2018 Zika virus (ZIKV) is an emerging flavivirus rapidly spreading throughout the tropical Americas. mosquitoes is the principal way of transmission of the virus to humans. ZIKV can be spread by transplacental, perinatal, and body fluids.
Acosta-Ampudia, Yeny +8 more
core +2 more sources
Epidemiology of childhood Guillan-Barre syndrome in the north west of Iran
BMC Neurology, 2007 Background and aims This study was carried out to investigate the incidence, annual time trend and some epidemiological and clinical features of Guillain-Barre syndrome in children in the north west of Iran. Materials and methods In this population-based
Karegarmaher Mohammad H +3 more
doaj +1 more source